Scarica l'app Stockscreener
5.65
7.38%
-0.45
Dopo l'orario di chiusura:
5.65
Precedente Chiudi:
$6.10
Aprire:
$5.1
Volume 24 ore:
5.05M
Relative Volume:
2.44
Capitalizzazione di mercato:
$561.06M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-2.8226
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
-8.28%
1M Prestazione:
-25.76%
6M Prestazione:
-36.16%
1 anno Prestazione:
-60.95%
Intervallo 1D:
$5.00
$5.84
Intervallo di 1 settimana:
$5.00
$6.19
Portata 52W:
$4.9102
$15.09
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
5.65 | 600.78M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
(SPRY) Volatility Zones as Tactical Triggers - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings - marketbeat.com
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals earnings missed by $0.13, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Q2 2026 Earnings Call Transcript - marketbeat.com
ARS Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ - The National Law Review
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action DeadlineContact the Firm Before October 5, 2026 - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS - marketbeat.com
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results - Investing News Network
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - aol.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report - Investing.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings - quiverquant.com
ARS Pharma Q2 Results: Revenue up 114% YoY, net loss widens - scanx.trade
ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss - Stock Titan
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY - TMX Newsfile
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) - TMX Newsfile
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ARS Pharmaceuticals, Inc. ... - Caledonian Record
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earni - GuruFocus
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - Barchart.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals Investors Face October Lawsuit Deadline - stl.news
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - YCharts
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ... - Caledonian Record
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - GlobeNewswire
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals - GlobeNewswire
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, - GlobeNewswire
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc. - Morningstar
SPRY Deadline Alert: The Gross Law Firm Reminds ARS - GlobeNewswire
First Trust Advisors LP Purchases New Shares in ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceu - The National Law Review
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - PR Newswire
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):